Last reviewed · How we verify

NCT04757142

PLASMA Chile (PLASMA Chile)

Completed Last updated 31 December 2024
What this trial tests

trial in Heart Failure in 246 participants. Completed in 12 November 2024.

Timeline
11 March 2021
Primary endpoint
26 April 2024
12 November 2024

Quick facts

Lead sponsorMedtronic Cardiac Rhythm and Heart Failure
StatusCompleted
Study typeOBSERVATIONAL
Enrollment246
Start date11 March 2021
Primary completion26 April 2024
Estimated completion12 November 2024
Sites6 locations across Chile

Conditions studied

Sponsor

Medtronic Cardiac Rhythm and Heart Failure — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multicenter, observational cohort study to collect data on Chilean patients diagnosed with Heart Failure with reduced ejection fraction, their treatments, and their progress in a real-world environment. Additional objectives will be analyzed, such as mortality, and the barriers, if any, to receiving the indicated treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Medtronic Cardiac Rhythm and Heart Failure trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04757142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing